Analysis of the United States Molecular Imaging Equipment and Radiopharmaceuticals Market, Forecast to 2023

Technology Advances and New Radiopharmaceuticals Maintain the Industry on a Growth Track
Share this:
     
Published: 6 Mar 2017

Molecular imaging can easily be described as the next frontier of medical imaging. In an era of value-based reimbursement, molecular imaging is set to play a significant role in quicker diagnosis, more accurate disease staging, and selection of targeted treatments. Launch of new radiopharmaceuticals across clinical areas other than cardiology and oncology such as neurology and orthopedics is also expected to drive greater adoption of molecular imaging as part of clinical care pathways. However, molecular imaging continues to face several challenges, notably the high cost of molecular imaging modalities and image scans, competition from lower cost modalities such as CT and MRI, and concerns over future supply of Tc-99m, a key SPECT radiopharmaceutical used for cardiac scans. This study analyzes existing trends in the hybrid molecular imaging and diagnostic radiopharmaceuticals markets with an emphasis on understanding strategies employed by market participants to address these myriad challenges. It also assesses both these markets in the context of changing regulatory and reimbursement policies in order to provide future market trends. This analysis will be critical in helping market participants create long-term viable strategies in order to remain competitive and ensure continuous innovation. This deliverable assesses future trends in molecular imaging equipment revenues as well as growth in the number of unit shipments over the next few years. This will provide value to market participants that design and manufacture molecular imaging equipment. Market participants will also be provided insights on recent industry and technology trends that are shaping the molecular imaging market. Radiopharmaceutical manufacturers will be provided with key insights on the evolving usage trends of workhorse FDG and Tc-99m radiopharmaceuticals and the increasing adoption of new radiopharmaceuticals across new clinical areas. Companies that are in the process of developing software to improve quantitation accuracy, lower dosages, and reduce scan times for both PET and SPECT will be provided with key insights on how the molecular imaging market is growing as well as the factors that are required to facilitate greater adoption of PET and SPECT technologies.

  1.  
  2.  
  3.  
  4.  
  5.  
  6.  
  7.  
  8.  
  9.  
  10.  
  11.  
  12.  
  13.  
  14.  
  15.  
  16.  
  17.  
  18.  
  19.  
  20.  
  21.  
  22.  
  23.  
  24.  
  25.  

Tools

Features of this research

SUBSCRIPTIONS

Help Desk

Full list of offices


For more information and general enquiries, contact Frost & Sullivan near you.

North America
tel: +1.877.463.7678

Select a location near you..